FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
WebMD3d
What to Know About the New Nasal Spray for Tough Depression
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Medindia10d
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Kelsey Warren [email protected]  609 218 4053 Investor contact: Lauren Johnson [email protected] ...
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being ...
Johnson & Johnson (NYSE:JNJ) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...
mindsitenews2d
Four Things You Should Know Before Starting Therapy
How can you make therapy work best for you? Here are a few tips. And a new study offers more evidence that teens are in trouble.
Purdue Exponent8d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...